Friday 18 April 2014

Exclusive: Biogen prices hemophilia drug on par with older therapies

The company's name is displayed on a billboard near the headquarters of Biogen Idec Inc. in Cambridge Biogen Idec Inc is pricing its newly-approved long-acting hemophilia drug to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually. The move could pressure rivals such as Pfizer Inc to lower prices for existing hemophilia treatments, which provide patients with life-saving infusions of a blood clotting agent, according to doctors and industry analysts. Biogen last month won U.S. and Canadian approval for Alprolix to treat hemophilia B, the more rare form of the condition that affects about 4,000 people in the United States and about 25,000 worldwide. The company is awaiting a decision on another drug to treat hemophilia A, a more common form of the disease, expected to come in the next few months.




via Health News Headlines - Yahoo News Read More Here..

No comments:

Post a Comment